FTC Report Reveals Prescription Drug Middlemen’s $1.6 Billion Revenue from Cancer Drugs
A recent FTC report exposes how prescription drug middlemen generated nearly $1.6 billion in additional revenue from cancer drugs by directing business to affiliated pharmacies. The report highlights the influence of major PBMs like CVS Caremark and Express Scripts in driving up drug costs, disadvantaging smaller pharmacies, and inflating prices for critical medications like cancer drugs. The findings are expected to prompt Congressional action to address rising drug costs and hold the industry accountable.
The New York Times Investigates Pharmacy Benefit Managers
The New York Times is conducting an investigation into pharmacy benefit managers, the entities that play a crucial role in determining which medications are covered by insurance and how much consumers have to pay for them. This inquiry aims to…